NEW YORK (GenomeWeb News) – Molecular diagnostics company Exosome Diagnostics has raised $5 million, it disclosed in a document filed with the US Securities and Exchange Commission last week.

The New York-based firm declined to comment, but in its amended Form D filed with the SEC it said that in total it is targeting $6 million in the offering. The type of securities offered is a mixture of debt; options, warrants or other rights to acquire another security; and security to be acquired upon exercise of an option, warrant, or other right to acquire security.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: epigenetic changes linked with high-altitude pulmonary edema, transcriptome profiling of maize leaf development, and more.

Stanford University researchers are studying top athletes to uncover genes linked to performance.

The UW's Wylie Burke and Dartmouth's Gilbert Welch argue that whole-genome testing may do more harm than good, and a related poll.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.